2018
Role of the androgen signaling axis in genitourinary malignancies.
Shinder B, Shupe A, Lee G, Stein M, Kim I, Singer E. Role of the androgen signaling axis in genitourinary malignancies. Translational Cancer Research 2018, 7: 1135-1142. PMID: 30701159, PMCID: PMC6349041, DOI: 10.21037/tcr.2018.03.41.Peer-Reviewed Original ResearchRenal cell carcinomaGenitourinary malignanciesAndrogen receptorBladder cancerRole of ARAdvanced disease stateProstate cancer developmentNovel therapeutic strategiesCell carcinomaTherapeutic armamentariumTherapeutic strategiesMortality rateCancer developmentMalignancyAndrogensDisease statesCancerCarcinomaProstateArmamentariumMolecular biologyDiseaseProgressionRoleReceptors
2017
Comparative effectiveness of laparoscopic versus open prostatectomy for men with low-risk prostate cancer
Parikh R, Patel A, Kim S, Kim I, Goyal S. Comparative effectiveness of laparoscopic versus open prostatectomy for men with low-risk prostate cancer. International Journal Of Surgery Oncology 2017, 2: e13. PMID: 29177226, PMCID: PMC5673152, DOI: 10.1097/ij9.0000000000000013.Peer-Reviewed Original ResearchLow-risk prostate cancerLow-risk prostate cancer patientsNational Cancer DatabaseProstate cancer patientsProstate cancerCancer patientsCancer DatabaseMortality rateComparative effectivenessAcademic/research centersCharlson-Deyo comorbidity scoreHigh-volume hospitalsSurgical margin statusAbove inclusion criteriaRisk of deathCase-control studyComorbidity scoreMargin statusSurgery typeBlack patientsInsurance statusOpen prostatectomyOdds ratioInclusion criteriaClinicopathologic parameters
2013
Active surveillance in men with low-risk prostate cancer: current and future challenges.
Han C, Parihar J, Kim I. Active surveillance in men with low-risk prostate cancer: current and future challenges. American Journal Of Clinical And Experimental Urology 2013, 1: 72-82. PMID: 25374902, PMCID: PMC4219278.Peer-Reviewed Original ResearchLow-risk prostate cancerActive surveillanceProstate cancerSurvival rateCancer-specific survival ratesProstate-specific antigen (PSA) screeningActive surveillance protocolsCost of overtreatmentActive surveillance programPSA kineticsAntigen screeningSurveillance protocolInstitutional protocolEligibility criteriaMortality rateNew biomarkersCancerSurveillance programLong-term studiesTreatment triggersInterventionMenGenetic testsSurveillanceContemporary review